JMA journal最新文献

{"title":"Dissemination of Information to Foreigners in Preparation for Natural Disasters.","authors":"Hatsune Kido, Soichiro Saeki","doi":"10.31662/jmaj.2024-0327","DOIUrl":"10.31662/jmaj.2024-0327","url":null,"abstract":"","PeriodicalId":73550,"journal":{"name":"JMA journal","volume":"8 2","pages":"658-659"},"PeriodicalIF":1.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of Bloodstream Infections in Pediatric Patients with Cancer during Febrile Neutropenia: A Retrospective Study.","authors":"Yukihiro Matsukawa, Jun Matsubayashi, Kenichi Sakamoto, Kohei Takashima, Yuhachi Ikeda, Makoto Osawa, Takashi Taga, Yoshihiro Maruo","doi":"10.31662/jmaj.2024-0369","DOIUrl":"10.31662/jmaj.2024-0369","url":null,"abstract":"<p><strong>Introduction: </strong>Bloodstream infections (BSIs) are a major concern in pediatric patients with cancer, especially during episodes of febrile neutropenia (FN). In this study, we aimed to evaluate the incidence of BSI across various pediatric malignancies and identify cancer subtypes associated with a heightened risk of BSI.</p><p><strong>Methods: </strong>This single-center, retrospective cohort study analyzed the electronic medical records of pediatric patients with cancer treated between April 2012 and March 2023. Eligible patients included those diagnosed with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), lymphoma, brain tumors, and solid tumors. For each chemotherapy course, we assessed BSI incidence and FN episodes.</p><p><strong>Results: </strong>This study included 152 pediatric patients who underwent 829 chemotherapy courses. The cohort comprised 21 patients with AML, 52 with ALL, 10 with lymphoma, 26 with brain tumors, and 43 with solid tumors. Compared to other cancer types, the AML group exhibited the highest proportion of BSI across all chemotherapy courses (17% vs. 4%-7%). During FN episodes, the AML cohort had a significantly higher BSI incidence (22%) than other groups (7%-13%). Notably, chemotherapy courses involving high-dose cytarabine (HD-CA) had a substantially higher BSI incidence (30%) among the patients with AML than courses without HD-CA (2%).</p><p><strong>Conclusions: </strong>Patients with AML have the highest risk of BSIs in pediatric malignancies, particularly during FN episodes. In addition, our findings highlight an association between BSIs and HD-CA use in patients with AML.</p>","PeriodicalId":73550,"journal":{"name":"JMA journal","volume":"8 2","pages":"560-567"},"PeriodicalIF":1.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovative Artificial Intelligence System in the Children's Hospital in Japan.","authors":"Akihiro Umezawa, Kazuaki Nakamura, Mureo Kasahara, Takashi Igarashi","doi":"10.31662/jmaj.2024-0312","DOIUrl":"10.31662/jmaj.2024-0312","url":null,"abstract":"<p><p>The evolution of innovative artificial intelligence (AI) systems in pediatric hospitals in Japan promises benefits for patients and healthcare providers. We actively contribute to advancements in groundbreaking medical treatments by leveraging deep learning technology and using vast medical datasets. Our team of data scientists closely collaborates with departments within the hospital. Our research themes based on deep learning are wide-ranging, including acceleration of pathological diagnosis using image data, distinguishing of bacterial species, early detection of eye diseases, and prediction of genetic disorders from physical features. Furthermore, we implement Information and Communication Technology to diagnose pediatric cancer. Moreover, we predict immune responses based on genomic data and diagnose autism by quantifying behavior and communication. Our expertise extends beyond research to provide comprehensive AI development services, including data collection, annotation, high-speed computing, utilization of machine learning frameworks, design of web services, and containerization. In addition, as active members of medical AI platform collaboration partnerships, we provide unique data and analytical technologies to facilitate the development of AI development platforms. Furthermore, we address the challenges of securing medical data in the cloud to ensure compliance with stringent confidentiality standards. We will discuss AI's advancements in pediatric hospitals and their challenges.</p>","PeriodicalId":73550,"journal":{"name":"JMA journal","volume":"8 2","pages":"354-360"},"PeriodicalIF":1.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prime Editing Corrects Multiple Mutations in the RSRSP Region of the <i>RBM20</i> Gene Using a Single Prime Editing Guide RNA.","authors":"Takahiko Nishiyama","doi":"10.31662/jmaj.2025-0004","DOIUrl":"10.31662/jmaj.2025-0004","url":null,"abstract":"","PeriodicalId":73550,"journal":{"name":"JMA journal","volume":"8 2","pages":"587-590"},"PeriodicalIF":1.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the Letter by Matsubara.","authors":"Masaki Mori","doi":"10.31662/jmaj.2024-0420","DOIUrl":"10.31662/jmaj.2024-0420","url":null,"abstract":"","PeriodicalId":73550,"journal":{"name":"JMA journal","volume":"8 2","pages":"664"},"PeriodicalIF":1.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe Chronic Mesenteric Ischemia in a Patient with Moyamoya Disease.","authors":"Yohei Yamamoto, Kazuki Tsukuda, Ai Kazama, Yoshiki Wada, Hiroki Uchiyama, Toru Kikuchi, Toshifumi Kudo","doi":"10.31662/jmaj.2024-0306","DOIUrl":"10.31662/jmaj.2024-0306","url":null,"abstract":"<p><p>Moyamoya disease is a rare cerebrovascular occlusive disorder, and its natural course remains incompletely understood. Although rare, extracranial arterial lesions can develop in patients with moyamoya disease. We report the case of a 35-year-old Japanese woman with moyamoya disease who was referred to our department for the treatment of severe chronic mesenteric ischemia. She had a several-year history of postprandial abdominal pain and experienced two episodes of gastric ulcer perforation in the past year. Enhanced computed tomography revealed that the patient had a common trunk of the celiac and superior mesenteric arteries, which was occluded at its origin. The patient underwent an aorta to superior mesenteric artery bypass with a great saphenous vein graft. The postoperative period was uneventful, and the patient is now free of symptoms. The present case suggests that a patient with moyamoya disease can develop symptomatic mesenteric arterial lesions.</p>","PeriodicalId":73550,"journal":{"name":"JMA journal","volume":"8 2","pages":"646-649"},"PeriodicalIF":1.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Factors Associated with Body-weight Reduction Induced by Semaglutide 1.0 mg Weekly in Patients with Type 2 Diabetes Mellitus.","authors":"Noboru Kurinami, Masafumi Takada, Kenji Ashida, Seigo Sugiyama, Akira Yoshida, Kunio Hieshima, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara, Katsunori Jinnouchi, Masatoshi Nomura, Hideaki Jinnouchi","doi":"10.31662/jmaj.2024-0366","DOIUrl":"10.31662/jmaj.2024-0366","url":null,"abstract":"<p><strong>Introduction: </strong>We examined the clinical factors associated with a decrease in weight induced by weekly semaglutide in patients with type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>Patients with T2DM who visited the Diabetes Care Center of Jinnouchi Hospital between June 2020 and October 2023 and were treated with semaglutide, 1.0 mg weekly, in addition to their ongoing medications were retrospectively registered. We measured body weight both before weekly administration of 1.0 mg semaglutide and 180 days after treatment and calculated the change in weight.</p><p><strong>Results: </strong>A total of 96 patients with T2DM were enrolled, with a mean body weight of 87.2 ± 17.1 kg and mean HbA1c of 7.3 ± 1.7% at baseline. The greater response group, defined as having 1.0 mg weekly semaglutide treatment-related weight reduction of more than 7.0%, comprised 23 patients (24.0%). Weekly 1.0 mg semaglutide treatment for 180 days significantly reduced body weight (-3.1 ± 4.8 kg, p < 0.001) and glycated hemoglobin (-0.39% ± 1.23%, p = 0.003). Multivariable logistic regression analysis found that pretreatment high-density lipoprotein (HDL)-cholesterol levels per 1.0 mg/dL (odds ratio [OR] 1.05; 95% confidence interval [CI] 1.01-1.09, p = 0.02) were independently and significantly associated with greater weight reduction after weekly 1.0 mg semaglutide treatment, while a switch from other glucagon-like peptide-1 receptor agonists (OR 0.31; 95% CI 0.11-0.87; p = 0.03) was independently and significantly associated with lesser weight reduction after weekly 1.0 mg semaglutide treatment. In receiver-operator characteristic analysis, the cutoff value of pretreatment HDL-cholesterol levels for the presence of greater response in weight reduction was 46 mg/dL (sensitivity 61%, specificity 62%; p = 0.03).</p><p><strong>Conclusions: </strong>Pretreatment HDL-cholesterol levels serve as important information for weekly treatment with 1.0 mg semaglutide in patients with T2DM and expectation of weight reduction.</p>","PeriodicalId":73550,"journal":{"name":"JMA journal","volume":"8 2","pages":"526-532"},"PeriodicalIF":1.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hybrid Surgery for Superior Mesenteric Vein Thrombosis: A Case Report.","authors":"Ryota Sasaki, Takaaki Maruhashi, Marina Oi, Ayumi Takahashi, Kanako Okazaki, Yutaro Kurihara, Yasushi Asari","doi":"10.31662/jmaj.2024-0305","DOIUrl":"10.31662/jmaj.2024-0305","url":null,"abstract":"<p><p>Superior mesenteric vein thrombosis (SMVT) is a rare condition characterized by thrombus formation in the superior mesenteric vein. SMVT is generally caused by abnormal blood coagulation, inflammation, or surgical interventions. This condition can lead to intestinal ischemia and necrosis due to blood flow stasis. We report the case of a man in his 60s who presented with abdominal pain and vomiting. Abdominal contrast-enhanced computed tomography shows a thrombus in the portal and superior mesenteric veins, and reduced contrast in the small intestine. Approximately 1.5 m of the necrotic jejunum was resected, an open management approach was undertaken, and anticoagulation with continuous intravenous heparin was initiated. On the fourth day of treatment, a thrombus was retrieved from the superior mesenteric vein within the main trunk of the portal vein using a stent clot retrieval device. The patient's bowel edema improved soon thereafter. This case of SMVT was successfully managed using a hybrid approach of bowel resection and transcatheter thrombus retrieval.</p>","PeriodicalId":73550,"journal":{"name":"JMA journal","volume":"8 2","pages":"633-636"},"PeriodicalIF":1.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095858/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the Improved Publicly-funded Newborn Hearing Screening Program.","authors":"Nao Doi, Ichiro Fukunaga, Taisuke Kobayashi, Kahori Hirose, Masamitsu Hyodo, Masanori Teshima","doi":"10.31662/jmaj.2024-0344","DOIUrl":"10.31662/jmaj.2024-0344","url":null,"abstract":"<p><strong>Introduction: </strong>To increase the coverage rate and effectiveness, universal newborn hearing screening (NHS) should be financed by public funding rather than individuals. This study investigated the impact of the publicly-funded NHS program on the detection rate and the time to diagnosis and initiation of intervention for children with congenital hearing loss.</p><p><strong>Methods: </strong>We compared two groups: one group included newborns born between April 2011 and March 2016 who either did not pass NHS or were referred due to high risk (Group 1); the other group included newborns born between April 2017 and March 2022 who met the same criteria (Group 2). The screening costs of Group 1 were covered by the guardians' payments, whereas those of Group 2 were covered by public funding. The NHS program in Group 2 exhibited improved screening methods, course, and timing of diagnostic hearing tests for referred newborns. The number of detected newborns with hearing impairment, the period between birth and the initial visit to a diagnostic institution, and the time to intervention were evaluated.</p><p><strong>Results: </strong>Group 2 had more newborns with hearing loss (n = 51) than Group 1 (n = 32), representing a significant difference (p = 0.005). Group 2 had more children with bilateral hearing loss (n = 29) than Group 1 (n = 21), but the difference was not significant. The duration until the diagnostic test was significantly reduced in Group 2 (58 days in Group 1 vs. 35 days in Group 2). The duration of intervention also was significantly reduced in Group 2 (147 days vs. 99 days).</p><p><strong>Conclusions: </strong>The improved program based on public funding achieved an increased number of detected infants with hearing loss. Additionally, it shortened the durations until the first diagnostic test to an institution and intervention. The new NHS program funded by local governments achieved improved effectiveness by unifying the screening method, the course of diagnostic hearing examination, and the follow-up.</p>","PeriodicalId":73550,"journal":{"name":"JMA journal","volume":"8 2","pages":"533-539"},"PeriodicalIF":1.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significant Increase in Excess Deaths after Repeated COVID-19 Vaccination in Japan.","authors":"Hideki Kakeya, Takeshi Nitta, Yukari Kamijima, Takayuki Miyazawa","doi":"10.31662/jmaj.2024-0298","DOIUrl":"10.31662/jmaj.2024-0298","url":null,"abstract":"<p><p>Although Japan recorded the world's highest rate of COVID-19 messenger ribonucleic acid (mRNA) vaccination doses per capita, COVID-19 cases and deaths exploded after the emergence of the Omicron variant, followed by a significant increase in excess deaths in 2022 and 2023. Although several hypotheses have been proposed to explain these phenomena, the truth remains to be established because sufficient studies and data disclosures have not been conducted to adequately investigate the possible contribution of mRNA vaccines. The causes of the excess deaths from not only COVID-19 but also other factors after repeated mRNA vaccinations must be elucidated, given this could provide valuable information to help combat future infectious disease outbreaks.</p>","PeriodicalId":73550,"journal":{"name":"JMA journal","volume":"8 2","pages":"584-586"},"PeriodicalIF":1.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}